Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Study Overview
Researchers are looking for new ways to treat people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are types of blood cancer. Researchers want to know if people who take nemtabrutinib compared to those who take the standard treatments in this study will live longer without their cancer growing, spreading or returning (progression free survival).
NATIONAL TRIAL REFERENCE NUMBER
NCT05624554
When you talk with your doctor or clinical team member, please have the national trial reference number available.
Resources
Patient Participation
Only a qualified healthcare professional can determine if you are eligible to take part in a clinical trial. However, this information may be useful in starting a conversation with your doctor.
Age Range
18+
Sex
All
Study Details
All patients who enroll in the trial will receive medication while on the study.
50% of patients will receive nemtabrutinib
50% of patients will receive either fludarabine plus cyclophosphamide plus rituximab (FCR) or bendamustine plus rituximab (BR)
Trial Phase
Trial Phase 3
In Phase 3 trials, researchers try to find out if a treatment works in a large number of people, usually about 1,000 to 5,000 participants who have the health condition the treatment is intended to treat. In vaccine trials, the participants may be healthy or have diseases or conditions. Phase 3 trials may happen in a doctor’s office, a clinic, or a hospital.
Start Date
End Date
- Actual study start date 03-16-2023
- Estimated primary completion date 05-19-2027
- Estimated study completion date 03-17-2031
Trial Locations
Sorry, there are no locations found.
What can you do next?
If you think this clinical trial might be a good fit and you are interested in taking part, take the next step to see if you are eligible.